R-CHOEP-14 regimen: Difference between revisions

	WikiDoc Resources for R-CHOEP-14 regimen
Articles
Most recent articles on R-CHOEP-14 regimen Most cited articles on R-CHOEP-14 regimen Review articles on R-CHOEP-14 regimen Articles on R-CHOEP-14 regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on R-CHOEP-14 regimen Images of R-CHOEP-14 regimen Photos of R-CHOEP-14 regimen Podcasts & MP3s on R-CHOEP-14 regimen Videos on R-CHOEP-14 regimen
Evidence Based Medicine
Cochrane Collaboration on R-CHOEP-14 regimen Bandolier on R-CHOEP-14 regimen TRIP on R-CHOEP-14 regimen
Clinical Trials
Ongoing Trials on R-CHOEP-14 regimen at Clinical Trials.gov Trial results on R-CHOEP-14 regimen Clinical Trials on R-CHOEP-14 regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on R-CHOEP-14 regimen NICE Guidance on R-CHOEP-14 regimen NHS PRODIGY Guidance FDA on R-CHOEP-14 regimen CDC on R-CHOEP-14 regimen
Books
Books on R-CHOEP-14 regimen
News
R-CHOEP-14 regimen in the news Be alerted to news on R-CHOEP-14 regimen News trends on R-CHOEP-14 regimen
Commentary
Blogs on R-CHOEP-14 regimen
Definitions
Definitions of R-CHOEP-14 regimen
Patient Resources / Community
Patient resources on R-CHOEP-14 regimen Discussion groups on R-CHOEP-14 regimen Patient Handouts on R-CHOEP-14 regimen Directions to Hospitals Treating R-CHOEP-14 regimen Risk calculators and risk factors for R-CHOEP-14 regimen
Healthcare Provider Resources
Symptoms of R-CHOEP-14 regimen Causes & Risk Factors for R-CHOEP-14 regimen Diagnostic studies for R-CHOEP-14 regimen Treatment of R-CHOEP-14 regimen
Continuing Medical Education (CME)
CME Programs on R-CHOEP-14 regimen
International
R-CHOEP-14 regimen en Espanol R-CHOEP-14 regimen en Francais
Business
R-CHOEP-14 regimen in the Marketplace Patents on R-CHOEP-14 regimen
Experimental / Informatics
List of terms related to R-CHOEP-14 regimen

Newer edit →

VisualWikitext

Revision as of 17:56, 31 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Etoposide-Prednisone regimen

Overview

R-CHOEP-14 regimen refers to a two-week regimen consisting of rituximab,cyclophosphamide, doxorubicin (hydroxydaunorubicin, vincristine (Oncovin), etoposide, and prednisone used to treat diffuse large B-cell lymphoma.^[1]

Regimen

RRituximab

CCyclophosphamide

HDoxorubicin (Hydroxydaunomycin)

OVincristine (Oncovin)

EEtoposide

PPrednisone

Indications

Diffuse large B-cell lymphoma^[1]

References

↑ ^1.0 ^1.1 Gang AO, Strøm C, Pedersen M, d'Amore F, Pedersen LM, Bukh A; et al. (2012). "R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group". Ann Oncol. 23 (1): 147–53. doi:10.1093/annonc/mdr058. PMID 21460380.

[pmid21460380-1] 1.0 ^1.1 Gang AO, Strøm C, Pedersen M, d'Amore F, Pedersen LM, Bukh A; et al. (2012). "R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group". Ann Oncol. 23 (1): 147–53. doi:10.1093/annonc/mdr058. PMID 21460380.

[1]

@@ Line 6: / Line 6: @@
 ==Overview==
-{{PAGENAME}} refers to a regimen consisting of [[rituximab]],[[cyclophosphamide]], [[doxorubicin|doxorubicin (hydroxydaunorubicin]], [[vincristine|vincristine (Oncovin)]], [[etoposide]], and [[prednisone]] used to treat [[diffuse large B-cell lymphoma]].<ref name="pmid21460380">{{cite journal| author=Gang AO, Strøm C, Pedersen M, d'Amore F, Pedersen LM, Bukh A et al.| title=R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. | journal=Ann Oncol | year= 2012 | volume= 23 | issue= 1 | pages= 147-53 | pmid=21460380 | doi=10.1093/annonc/mdr058 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21460380  }} </ref>
+{{PAGENAME}} refers to a two-week regimen consisting of [[rituximab]],[[cyclophosphamide]], [[doxorubicin|doxorubicin (hydroxydaunorubicin]], [[vincristine|vincristine (Oncovin)]], [[etoposide]], and [[prednisone]] used to treat [[diffuse large B-cell lymphoma]].<ref name="pmid21460380">{{cite journal| author=Gang AO, Strøm C, Pedersen M, d'Amore F, Pedersen LM, Bukh A et al.| title=R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. | journal=Ann Oncol | year= 2012 | volume= 23 | issue= 1 | pages= 147-53 | pmid=21460380 | doi=10.1093/annonc/mdr058 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21460380  }} </ref>
 ==Regimen==